The major event in normal erectile function is relaxation of the smooth muscle both within the penile arterial system and the cavernosal tissue. The cavernosal smooth muscle is indistinguishable from peripheral vascular smooth muscle from a physiological point of view, ie both are mediated by the NO-cGMP pathway. In man, the major reason for erectile dysfunction (ED) is abnormal smooth muscle relaxation', where the smooth muscle of the cavernosa fails to trap blood within the cavernosa (trapping requires a high intracorporeal pressure). The failure of the cavernosal muscle to relax may be due to inadequate stimulation of the muscle or simply noncompliance of the smooth muscle itself. Therefore, attempts to reverse this abnormal smooth muscle relaxation should be directed at either increasing stimulation to the muscle andaor reversing the poor compliance of the muscle tissue itself. Because the major and most ef®cient pathway for smooth muscle relaxation is the NO-cGMP pathway, any medication that affects this system should prove to be more potent than other alternate pathways of corporal smooth muscle relaxation, as is evidenced from the clinical observations with current intracorporeal instilled drugs. Because the peripheral vascular smooth muscle is indistinguishable physiologically from the muscle of the cavernosal system, any oral drug must be able to differentiate the two smooth muscle compartments to prevent systemic side effects that could render such drugs clinically useless. At the present time, there are no methods to improve smooth muscle compliance but advances in tissue engineering may allow us to accomplish this in the future.
Introduction
The development of an oral drug for erectile dysfunction holds promise as a major blockbuster for any pharmaceutical ®rm. This is evidenced by the phenomenal commercial success of sildena®l citrate, which was introduced to the market in early 1998 and helped distinguish 1998 as the`Year of the Penis'. 1 The success of sildena®l, although based somewhat on serendipity, can be viewed critically from a scienti®c point of view to demonstrate that the compound ful®lls, in the opinion of this author, a number of physiological criteria that any potential successful oral drug for ED must ful®ll. This review will attempt to identify and discuss some of these criteria.
Physiology of erection
In order to understand how any oral drug affects penile erection, a knowledge of the physiological events involved in the normal erectile response is necessary. These events have been presented in detail in other reviews, but it suf®ces to summarize here that the major pathway in the induction of an erection appears to be the NO-cGMP pathway. 2, 3 NO (nitric oxide) emanates from the endings of the cavernosal nerve in response to a stimulus and the enzyme that synthesizes NO, termed neuronal nitric oxide synthase (nNOS), forms this lipophilic gas (NO) which diffuses rapidly into the neighboring smooth muscle to activate guanyl cyclase. Guanyl cyclase forms cGMP which induces a series of biochemical responses including activation of a variety of enzymes that ultimately lead to unbinding of intracellular Ca 2 and smooth muscle relaxation. cGMP is normally degraded within the smooth muscle cell by the phophodiesterase enzyme (PDE) which in the penile cavernosal cells consists mainly of the type V isozyme. 4 NO not only induces relaxation of the cavernosal smooth muscle cells but has a major role in relaxing the vascular smooth muscle within the cavernosal arterial tree. In fact, the ®rst physiological vascular event that is measurable in the initiation of an erection is relaxation of the smooth muscle of the cavernosal arterial system (secondary to cavernosal nerve stimulation). Indeed, the smooth muscle of the penis acts physiologically similarly to the smooth muscle of the peripheral vascular system and many consider the penis to be a specialized appendage of the peripheral vascular system. The major important physiological impact of this relationship is that all oral compounds that enter the penile vascular tree must ®rst traverse the peripheral vascular system. Hence, the peripheral vascular tree is at risk of being`stimulated' by the compounds that are directed towards the cavernosal smooth muscle. It is obvious that the ability of a compound to recognize the cavernosal smooth muscle (to induce vasorelaxation) while simultaneously being able to`ignore' the periphery would have an advantage over one that does not have this ability.
The smooth muscle of the cavernosa has a variety of accessory pathways that can be pharmacologically exploited in the development of an erection (vasorelaxation). Two such pathways are the cAMP pathway that is responsive to prostaglandin E1 and the adrenergic receptor pathway that involves the adrenergic receptor on the cell membrane. It is this latter pathway that is pharmacologically responsive to alpha adrenergic blockers such as phentolamine. 5, 6 Clinical evidence suggests that if one compares ef®cacy of the three pharmacologic agents that are currently utilized in the intracorporeal (nonoral) treatment of ED, one would conclude that they should be ordered as follows: papaverine b PGE1 b phentolamine. The inference from this clinical observation is that, since papaverine, a phosphodiesterase inhibitor, is the most`potent' of the three drugs that utilize this pathway in their mode of action, it should stand a statistically better chance of being ef®cacious in relaxing the corporal smooth muscle.
Etiology of erectile dysfunction
The development of any drug for erectile dysfunction (ED) must take into consideration the cause of the dysfunction. For example, most commercial enterprises would probably have more enthusiasm for developing a drug that can treat the majority of patients with ED rather than for an etiology that affects only 1% of these patients. There is general agreement that the major cause of ED is considered to be vasculogenic. 7 In reality, this is somewhat of a misnomer because the major`hit' in the pathophysiology of ED is the inability of the cavernosal tissue (smooth muscle) to`trap' blood within the cavernosa (maintaining the erection). The current thinking is that the smooth muscle of the penis is somehow altered (either in its function or its structure) in certain states such as aging, diabetes or exposure to certain medications (eg antihypertensives) which affect the function of cavernosal smooth muscle. 8 Therefore, the major`hit' is a myopathy of unknown etiologies. 9 When a critical amount of smooth muscle within the cavernosa is affected by this myopathy, the cavernosal muscle is unable to relax enough to allow attainment of intracorporeal pressure suf®cient to compress the subtunical veins and prevent the egress of blood out of the cavernosa. Consequently, drugs that enhance corporal smooth muscle relaxation theoretically may be effective as an erectogenic agent.
Drug delivery
Orally administered drugs are at the mercy of the nuances of the GI tract (absorption), the kidneys and liver (degradation) and the vascular system (binding). All three parameters must be managed in concert in order to build a compound that is easy to digest, attains appreciable levels in the blood stream that can reach the target tissue without affecting the vascular system, and accumulates in only minute amounts in non-target tissues. Biochemically, it is possible to manipulate compounds to either increase or decrease their absorptive, degradative andaor binding characteristics and, thus, to develop a`designer' drug. For example, one could envision a drug that has an onset of action hours after ingestion that is suitable as a`day after' pill rather than an`on demand' pill. Regardless of how the drug is designed, optimal ef®cacy with minimal side effects is of paramount importance.
Tissue selectivity
As enumerated above, the ability of a drug to select the target tissue (penis) while bypassing other tissues (vascular system) would enhance its effectiveness as an erectogenic agent. Therefore, the characteristics of the penile smooth muscle that separate it from the peripheral vascular tissue should be sought in drug development. The corporal smooth muscle is known to be rich in type V PDE, but unfortunately, type V PDE is also found in the aorta and in some parts of the peripheral vascular smooth muscle. The predominant nNOS in the penis is different from the other nNOS seen in the rest of the vascular system in that it contains a 34 amino acid insert. This penile nNOS (PnNOS) could be one selective site of action directed at the penile smooth muscle that`bypasses' the peripheral vascular tissue.
Summary
While this author is not an expert in drug development or smooth muscle physiology, it seems reasonable to assume, based on currently available knowledge, that the ideal drug for the treatment of ED should somehow involve the NO-cGMP system and should target some aspect of the corporal smooth muscle. This mode of action also has the potential to distinguish cavernosal from peripheral smooth muscle. Not surprisingly, sildena®l ®ts the criteria, 10 since it is a type V PDE enzyme inhibitor that works by enhancing smooth muscle relaxation via prolongation of cGMP within the cavernosal smooth muscle. The drug is rapidly absorbed and reaches maximum serum levels at the doses recommended within an hour, has a half-life of 4 ± 6 h, and is poorly accumulated in other tissues. However, it is not a purely speci®c (100%) type V PDE inhibitor and does cross-react with other PDE enzymes. This limited selectivity for type V PDE thereby prevents the use of much higher doses of sildena®l and hence, attainment of much higher serum concentrations.
Conclusion
Because the major cause of ED seems to be some form of a cavernosal myopathy, future research efforts should be directed at enhancing corporal smooth muscle responsiveness either by re-engineering the myocytes or by promoting relaxation of the smooth muscle by upregulating the activity andaor content of NO via the PnNOS enzyme. 11 Efforts in these two areas are currently in their embryonic stage.
